More Articles Back to Article

Capmatinib granted priority review as treatment for NSCLC

Priority review was granted by the FDA to Novartis' new drug application for its investigational drug INC280, or capmatinib, which is being assessed as a first-line treatment for patients diagnosed with locally advanced or metastatic MET exon 14 skipping mutated non-small cell lung cancer. Specialty Pharmacy Times (2/11)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!